CME vs. Morningstar: Which Financial Stock Is a Better Buy in 2026?
Key PointsCME Group posted a net margin of about 62% in 2025, and its long-term debt equaled about 12% of its shareholders' equity at year-end.
Investors often find themselves deciding between market infrastructure and financial data providers when considering which stocks to buy. In this analysis, we compare CME Group (NASDAQ: CME), a derivatives exchange operator, and Morningstar (NASDAQ: MORN), an investment research and data provider. Both companies play crucial roles in global financial markets, and their financial health and risk profiles are compared herein.
CME Group facilitates trading in futures and options across six asset classes, such as interest rates and energy. The company's 2025 annual report highlights a strategic partnership with Google Cloud, Alphabet's subsidiary (NASDAQ: GOOGL), signed in 2021. Additionally, CME's collaboration with Flutter Entertainment's FanDuel (NYSE: FLUT) resulted in a prediction markets app for retail customers, launched in December 2025.
However, the report notes that one firm accounted for 12% of CME's clearing and transaction fees revenue in 2025, indicating a significant concentration risk.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
